{
  "docId": "019de077-5130-7668-92cb-6c77396e6bd2",
  "docSlug": "e021a2de9332664c5094197b4bc248cd",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 157 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 49,
  "pageCount": 132,
  "prevPage": 48,
  "nextPage": 50,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "Slide 49 of a presentation deck.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-5130-7668-92cb-6c77396e6bd2/49",
  "deckHref": "/decks/019de077-5130-7668-92cb-6c77396e6bd2",
  "deckJsonHref": "/decks/019de077-5130-7668-92cb-6c77396e6bd2.json",
  "deckAnchorHref": "/decks/019de077-5130-7668-92cb-6c77396e6bd2#slide-49",
  "components": [
    {
      "bbox": {
        "h": 0.11,
        "w": 0.93,
        "x": 0.035,
        "y": 0.197
      },
      "kind": "table",
      "text": "Trial: Phase I/II ALAFOSS-01 NCT06599502; Population: Metastatic or locally advanced colorectal cancer, pancreatic ductal adenocarcinoma and NSCLC, with KRASG12D mutation; Patients: 430; Design: Open-label, multi-centre study, Module 1: AZD0022 monotherapy, Module 2: AZD0022 + other anti-cancer agents; Endpoints: Primary endpoints: safety and tolerability, ORR, Secondary endpoints: PK parameters and efficacy; Status: FPCD: Q4 2024, Data anticipated: >2025",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e09339e2-ad43-4e20-92f0-c3e3891488b8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.16,
        "w": 0.39,
        "x": 0.035,
        "y": 0.045
      },
      "kind": "title",
      "text": "AZD0022 (KRASG12D) Solid tumours",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "175ab7ee-b544-4ec0-a2d1-2df4aed7cdad",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 120,
      "from": 6,
      "beatId": "0c127c3c-ea10-450c-b057-64b7f7a0f03c",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Detailed overview of AstraZeneca's pipeline and portfolio",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}